Department of Medicine, Division of Nephrology, Columbia University, New York, New York; Columbia University Renal Epidemiology Group, New York, New York.
Department of Pathology and Cell Biology, Columbia University, New York, New York.
Am J Kidney Dis. 2024 Mar;83(3):306-317. doi: 10.1053/j.ajkd.2023.08.022. Epub 2023 Oct 24.
RATIONALE & OBJECTIVE: Some living donor kidneys are found to have biopsy evidence of chronic scarring and/or glomerular disease at implantation, but it is unclear if these biopsy findings help predict donor kidney recovery or allograft outcomes. Our objective was to identify the prevalence of chronic histological changes and glomerular disease in donor kidneys, and their association with donor and recipient outcomes.
Retrospective cohort study.
SETTING & PARTICIPANTS: Single center, living donor kidney transplants from January 2010 to July 2022.
Chronic histological changes, glomerular disease in donor kidney implantation biopsies.
For donors, single-kidney estimated glomerular filtration rate (eGFR) increase, percent total eGFR loss, ≥40% eGFR decline from predonation baseline, and eGFR<60mL/min/1.73m at 6 months after donation; for recipients, death-censored allograft survival.
Biopsies were classified as having possible glomerular disease by pathologist diagnosis or chronic changes based on the percentage of glomerulosclerosis, interstitial fibrosis/tubular atrophy, and vascular disease. We used logistic regression to identify factors associated with the presence of chronic changes, linear regression to identify the association between chronic changes and single-kidney estimated glomerular filtration rate (eGFR) recovery, and time-to-event analyses to identify the relationship between abnormal biopsy findings and allograft outcomes.
Among 1,104 living donor kidneys, 155 (14%) had advanced chronic changes on implantation biopsy, and 12 (1%) had findings suggestive of possible donor glomerular disease. Adjusted logistic regression showed that age (odds ratio [OR], 2.44 per 10 years [95% CI, 1.98-3.01), Hispanic ethnicity (OR, 1.87 [95% CI, 1.15-3.05), and hypertension (OR, 1.92 [95% CI, 1.01-3.64), were associated with higher odds of chronic changes on implantation biopsy. Adjusted linear regression showed no association of advanced chronic changes with single-kidney eGFR increase or relative risk of eGFR<60mL/min/1.73m. There were no differences in time-to-death-censored allograft failure in unadjusted or adjusted Cox proportional hazards models when comparing kidneys with chronic changes to kidneys without histological abnormalities.
Retrospective, absence of measured GFR.
Approximately 1 in 7 living donor kidneys had chronic changes on implantation biopsy, primarily in the form of moderate vascular disease, and 1% had possible donor glomerular disease. Abnormal implantation biopsy findings were not significantly associated with 6-month donor eGFR outcomes or allograft survival.
PLAIN-LANGUAGE SUMMARY: Kidney biopsies are the gold standard test to identify the presence or absence of kidney disease. However, kidneys donated by healthy living donors-who are extensively screened for any evidence of kidney disease before donation-occasionally show findings that might be considered "abnormal," including the presence of scarring in the kidney or findings suggestive of a primary kidney disease. We studied the frequency of abnormal kidney biopsy findings among living donors at our center. We found that about 14% of kidneys had chronic abnormalities and 1% had findings suggesting possible glomerular kidney disease, but the presence of abnormal biopsy findings was not associated with worse outcomes for the donors or their recipients.
一些活体供肾在植入时被发现存在活检证据的慢性瘢痕和/或肾小球疾病,但尚不清楚这些活检发现是否有助于预测供肾恢复或移植物结局。我们的目的是确定供体肾脏中慢性组织学变化和肾小球疾病的患病率,并确定其与供体和受者结局的关系。
回顾性队列研究。
2010 年 1 月至 2022 年 7 月,单中心活体供肾移植。
供体肾脏植入活检中的慢性组织学变化、肾小球疾病。
对于供体,单肾估计肾小球滤过率(eGFR)增加、总 eGFR 损失百分比、与供体基线相比 eGFR 下降≥40%、以及 eGFR<60mL/min/1.73m 在供肾后 6 个月;对于受者,死亡风险校正的移植物存活率。
根据肾小球硬化、间质纤维化/肾小管萎缩和血管疾病的百分比,将活检分类为存在可能的肾小球疾病,由病理学家诊断或慢性变化。我们使用逻辑回归来确定与慢性变化存在相关的因素,使用线性回归来确定慢性变化与单肾估计肾小球滤过率(eGFR)恢复之间的关系,以及使用时间事件分析来确定异常活检发现与移植物结局之间的关系。
在 1104 例活体供肾中,155 例(14%)在植入活检中存在晚期慢性变化,12 例(1%)有提示可能存在供体肾小球疾病的发现。调整后的逻辑回归显示,年龄(每增加 10 岁的比值比[OR],95%CI 为 1.98-3.01)、西班牙裔种族(OR,1.87[95%CI,1.15-3.05])和高血压(OR,1.92[95%CI,1.01-3.64])与植入活检中慢性变化的几率更高相关。调整后的线性回归显示,晚期慢性变化与单肾 eGFR 增加或 eGFR<60mL/min/1.73m 的相对风险无关。在未调整和调整后的 Cox 比例风险模型中,比较有慢性变化的肾脏和无组织学异常的肾脏时,在死亡风险校正的移植物失败时间上没有差异。
回顾性研究,缺乏测量的 GFR。
大约每 7 个活体供肾中有 1 个在植入活检中存在慢性变化,主要表现为中度血管疾病,1%存在可能的供体肾小球疾病。异常的植入活检发现与 6 个月供体 eGFR 结局或移植物存活率无显著相关性。